The ICR responds to decision by NICE not to recommend pembrolizumab as first-line treatment for advanced head and neck cancer 15 Jan 2020
The ICR responds to approval of abiraterone as first-line treatment for advanced prostate cancer on the NHS in Scotland 13 Jan 2020